Ainos Inc (AIMD): $AIMD LOADING ZONE HERE! HEARING HUGE UP...

$AIMD LOADING ZONE HERE! HEARING HUGE UPDATE COMING...

QuicKtip · 2024-06-11T14:13:49.6370000Z

$AIMD LOADING ZONE HERE! HEARING HUGE UPDATE COMING... https://x.com/StockOnHighALer/status/1800522691667251468

Play Episode

7min

Proactive - Interviews for investors

CleanSpace eyes 30% growth, EBITDA breakeven

CleanSpace Holdings Ltd CEO Gabrielle O’Carroll talked with Proactive about AIM's Small and Midcap Conference about the company’s growth trajectory and product innovation in powered air purifying respirators (PAPRs). CleanSpace was founded in 2009, based on an innovation developed during the SARS epidemic. The company's differentiator is its lightweight, head-mounted respirators that contrast with the bulkier waist-mounted models commonly available in the industrial market. “We are steadily approaching that breakeven EBITDA, profitable EBITDA position, which is our goal,” O’Carroll said. O’Carroll explained that CleanSpace's respirators are well suited for industrial sectors like mining, infrastructure, and petrochemicals. The products are marketed in key regions including the United States, Western Europe, and Australia. The company has 52 employees and recorded AU$9.2 million in revenue in the first half, up 26% year-over-year. CleanSpace is targeting annual revenue growth of 25–30% and expects to achieve positive EBITDA soon. To drive this, the company is focused on raising brand awareness, engaging directly with end users, and supporting occupational hygienists and safety managers. CleanSpace is also investing in R&D to support future product launches. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #CleanSpaceHoldings #IndustrialSafety #RespiratoryProtection #PAPR #WorkplaceSafety #OccupationalHealth #ASXStocks #HealthTech #EBITDA #MiningSafety #InfrastructureSafety #ProactiveInvestors

Proactive - Interviews for investors

COSOL Sees U.S. market as key growth driver

COSOL Limited Managing Director Scott McGowan talked with Proactive at AIM's Small and Midcap Conference about the company’s role in driving operational efficiency across asset-intensive industries. COSOL Limited works with organisations in mining, oil and gas, utilities, and public infrastructure to enhance the performance of their physical assets. McGowan explained the company’s core service as unlocking value by helping clients reduce costs through better asset management. “We look at ways that we can save them real dollars to be able to manage that asset more effectively,” he said. The company’s client list includes major names such as Glencore, Rio Tinto, BHP, and several government departments. COSOL provides the systems and processes behind the scenes to manage these organisations’ equipment and facilities, potentially impacting hundreds of millions in operational costs. Even a 2–3% improvement, McGowan said, “makes a significant difference to their bottom line.” COSOL has grown revenue from AUD 30 million to over AUD 110 million since listing. It is now targeting organic growth in the mid-teens and exploring earnings-accretive acquisitions. McGowan also highlighted COSOL’s presence in the U.S., describing it as the company’s largest potential market, where current operations may be expanded through acquisition. #COSOL #ASXStocks #ScottMcGowan #AssetManagement #MiningTech #Utilities #PublicInfrastructure #OperationalEfficiency #DataSolutions #IndustrialSoftware #GrowthStocks #USExpansion #InvestingInTech -

Proactive - Interviews for investors

AuKing prepares for gold mining at Mt Freda site

AuKing Mining Ltd managing director Paul Williams talked with Proactive about the company's latest update on its Cloncurry Project in Queensland, focusing on the Mt Freda deposit. Williams confirmed that with Orion Resources nearing acquisition completion, AuKing is preparing to restart mining operations at the historical Mt Freda gold mine. Williams highlighted Mt Freda as a top target for redevelopment due to its existing mining lease and approvals, as well as a current resource estimate of around 100,000oz. "We really don't want to start a mining operation unless we've got reserves in the resource estimate," he explained, outlining the company’s aim to confirm and expand those figures through an upcoming drilling program. In addition to resource verification, AuKing is evaluating two processing options: existing vat leaching pits and a nearby cavern in-leach circuit at Lorena. Williams also noted the broader potential in the surrounding six square kilometre Mt Freda Complex, which contains multiple historical deposits, hinting at further exploration upside. Drilling is expected to start within weeks of the acquisition's financial close in April, with results anticipated in the months following. Williams described the program as "a fascinating exercise," indicating renewed momentum behind the restart strategy. For more updates from AuKing Mining Ltd and other resource sector insights, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #AuKingMining #MtFreda #GoldMining #ASXAKN #CloncurryProject #ResourceDrilling #MiningRestart #QueenslandMining #JuniorMining #GoldExploration #MiningInvestment #ASXResources #OrionResources

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Followers	17
Posts	4747
Boards Moderated	0
Alias Born	08/23/2022

Volume:	20
Day Range:
Bid:	0.46
Ask:	0.50
Last Trade Time:	5:05:45 AM EDT
Total Trades:	1

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

AIMD Detailed Quote

Recent AIMD News

More AIMD News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent AIMD News

Go Ad-Free